8-K: Lifeway Foods Rejects Danone's Acquisition Proposal, Citing Undervaluation and Invalid Shareholder Agreement

Lifeway Foods has rejected Danone's revised acquisition proposal of $27 per share, stating it substantially undervalues the company and citing an invalid shareholder agreement.

Summary

• Lifeway Foods rejected Danone's revised proposal to acquire all outstanding shares for $27 per share.
• The board believes the proposal undervalues the company, citing strong growth and future potential.
• Lifeway has experienced 20 consecutive quarters of year-over-year topline growth.
• The company's annual revenue grew from $94 million in 2019 to $160 million in 2023, a 71% increase.
• Gross profit increased by 92% over the same period, with a 18% cumulative annual growth rate.
• Adjusted EBITDA reached $22 million in 2023 and is projected to grow to between $45 million and $50 million by 2027.
• The board also contends that a shareholder agreement with Danone is invalid under Illinois law.
• The company believes its standalone plan offers superior value to shareholders compared to Danone's offer.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong historical performance and future growth projections, but there is some uncertainty due to the rejected acquisition offer and legal dispute.

Positives

• Lifeway has demonstrated strong financial performance with consistent topline growth.
• The company has experienced significant revenue and gross profit increases over the past five years.
• Lifeway is projecting substantial growth in Adjusted EBITDA over the next few years.
• The company's board is committed to maximizing shareholder value.
• Lifeway is the number one kefir brand and is experiencing double-digit growth.
• The company has a strong market position and is benefiting from increasing consumer awareness of gut health.

Negatives

• Danone's acquisition proposal was deemed to undervalue the company.
• There is a dispute over the validity of a shareholder agreement with Danone.
• The shareholder agreement is considered anticompetitive and potentially harmful to minority shareholders.

Risks

• The company faces risks related to price competition and changing consumer preferences.
• There are risks associated with the introduction of new products and customer acceptance.
• The company's future performance is subject to various market and economic factors.
• The legal dispute over the shareholder agreement could have implications for the company's future.

Future Outlook

Lifeway forecasts annual Adjusted EBITDA to grow from $22 million in 2023 to between $45 million and $50 million in 2027. The company believes it has strong potential for long-term growth and margin expansion.

Management Comments

• The Board determined that Danone's $27.00 per share proposal substantially undervalues the Company.
• The Board believes it has strong potential to provide superior value to all shareholders as compared to Danone's revised proposal.
• Lifeway's Board and management are committed to ensuring that all shareholders are able to realize the full potential value of their investment.

Industry Context

The announcement highlights the growing consumer interest in gut health and probiotic products, which is driving Lifeway's growth. The rejection of the acquisition offer suggests confidence in the company's standalone potential within the competitive food and beverage industry.

Comparison to Industry Standards

• Lifeway's 788% total shareholder return over the past five years significantly outperforms other high-growth food and beverage peers as well as the S&P 500.
• The company's 14% cumulative annual growth rate (CAGR) in revenue and 18% CAGR in gross profit from 2019 to 2023 are strong indicators of its performance compared to industry averages.
• The projected Adjusted EBITDA growth to $45-50 million by 2027 suggests a strong trajectory compared to peers in the fermented foods sector.
• The rejection of Danone's offer, which implies a 7.5x-8.5x EBITDA multiple, indicates that Lifeway believes it is worth more than industry standard multiples for similar companies.

Legal Proceedings

• There is a legal dispute regarding the validity of a shareholder agreement with Danone.

Stakeholder Impact

• Shareholders are impacted by the rejection of the acquisition offer and the potential for higher value through the company's standalone plan.
• Employees are impacted by the company's continued growth and strategic direction.
• Customers will continue to have access to Lifeway's products.
• Suppliers and creditors are impacted by the company's financial performance and strategic decisions.

Next Steps

• Lifeway will continue to execute its standalone plan.
• The company will continue to evaluate strategic options to maximize shareholder value.
• The company will address the legal issues surrounding the shareholder agreement.

Key Dates

Keywords

Lifeway Foods, Danone, acquisition, kefir, shareholder agreement, EBITDA, valuation, growth, probiotics, Illinois law